Figure 4 |. Teixobactin is efficacious in three mouse models of infection.

a, Single dose treatment (i.v., 1 h post-infection, 6 mice per group) with teixobactin and vancomycin in septicemia protection model using MRSA. Survival is depicted 48 h after infection. b, Single dose (i.v., 2 h post-infection, 4 mice per group) treatment with teixobactin and vancomycin in neutropenic mouse thigh infection model using MRSA. For drug-treated animals, thigh colony-forming units (c.f.u.) were determined at 26 h post-infection. For controls, c.f.u. in thighs were determined at 2 h and 26 h post-infection. c, Two dose treatment, 5 mice per group, with teixobactin (i.v., 24 h and 36 h post-infection) and single dose treatment with amoxicillin (subcutaneous, 24 h post-infection) in immunocompetent lung infection model using S. pneumoniae. Lung c.f.u. were determined at 48 h post-infection. The c.f.u. from each mouse are plotted as individual points and error bars represent the deviation within an experimental group. *P < 0.05, ***P < 0.001 (determined by non-parametric log-rank test).